CD163 and bronchiolitis obliterans syndrome: CD68+ TAM were present with a median of 9.3% in GO patients and 8.7% in BO patients, while CD163+ TAM were present with a median of 1% in GO patients and 5% in BO patients; in neither case the differences were statistically significant (Table 1 and Figure 2).